The need for such a system arises from the extraordinary complexity of the tumor microenvironment, or TME. A tumor is not simply a mass of malignant cells. It is an evolving community that includes immune cells, fibroblasts, blood vessels, extracellular matrix and signaling molecules, all interacting with one another and with cancer cells. These components can either restrain tumor growth or help cancer evade immune attack. Bulk transcriptomics, which measures RNA from a mixed tissue sample, provides a broad molecular snapshot of this environment, but the signal is blended together. A high abundance of a particular immune-cell signature, for example, may reflect genuine infiltration or changes in gene activity within neighboring cells. Computational deconvolution attempts to untangle this mixture by estimating the relative contribution of different cell types from their characteristic expression patterns.

In practice, however, TME analysis often remains fragmented. A researcher may need one program to normalize expression data, another to estimate immune-cell abundance, a third to classify molecular subtypes, and additional tools to calculate correlations or associate the results with patient survival. Each transition can introduce technical inconsistencies, incompatible file formats or undocumented processing choices. Local installation can also be difficult because bioinformatics packages depend on specific programming languages, libraries and operating-system configurations. IOBRportal addresses these problems by organizing the analysis as a continuous, workflow-centric process. Rather than treating each function as an isolated application, it links preprocessing, TME deconvolution, downstream statistical analysis and visualization so that intermediate results can be carried forward in a more consistent and reproducible manner.

The platform builds on the researchers’ earlier IOBR software package for R, a widely used programming environment for statistical computing and bioinformatics. R packages can offer substantial flexibility, but they typically require users to understand coding, manage dependencies and prepare data in precisely the expected format. IOBRportal places a browser-based interface over the analytical framework, shifting much of that technical burden to a cloud environment. The underlying principle is similar to using a remote laboratory instrument: the user supplies appropriately formatted data and selects an analysis path, while the platform handles computational execution. This approach does not eliminate the need for careful experimental design or statistical judgment, but it may lower the entry barrier for researchers who have biological expertise without extensive programming experience.

A central resource within IOBRportal is its large, curated sample collection. By combining many transcriptomic datasets, researchers can compare tumor-microenvironment patterns across cohorts and cancer types rather than relying on a single study. Large collections are particularly valuable because biological signals can be obscured by small sample sizes, batch effects or unusual characteristics of one patient group. In transcriptomics, a batch effect is a systematic difference caused by laboratory conditions, sequencing platforms or processing dates rather than by biology. Careful preprocessing and normalization are therefore essential before samples can be meaningfully compared. The platform is intended to support these early steps as part of the same workflow, while also permitting investigators to bring in private or newly generated data for analysis alongside public resources.

The authors illustrate the system with a case study in gastric cancer, using it to resolve tumor-microenvironment-associated molecular states. Such states can be thought of as recurring combinations of gene-expression patterns and cellular features that distinguish one tumor from another. Two cancers that look similar under a microscope may have very different immune landscapes: one may contain activated immune cells capable of recognizing malignant cells, while another may be dominated by suppressive cell populations or physical barriers that limit immune access. Identifying these patterns can help researchers formulate explanations for why patients respond differently to immunotherapies. The study presents IOBRportal as a tool for revealing these distinctions through integrated analysis, although the reported work does not establish that the resulting classifications are themselves ready for clinical decision-making.

A second example focuses on lung adenocarcinoma and links transcriptomic stratification with genomic mutations. This connection is important because gene expression and DNA alterations describe different layers of tumor biology. Genomic analysis identifies changes in the DNA sequence, such as mutations that activate growth pathways or alter the behavior of cancer cells. Transcriptomics measures the RNA molecules produced as genes are used, capturing the combined effects of mutations, cell identity, environmental signals and treatment history. A mutation may therefore be associated with a characteristic immune environment, but that relationship is not automatic: it can vary among patients and may be influenced by tumor purity, smoking history, prior therapy or other factors. By placing molecular states and mutation data into a shared analytical framework, IOBRportal can help researchers search for such relationships and generate hypotheses about how cancer genetics shapes immune interactions.

The platform’s integrated design could also accelerate analyses that are increasingly central to immuno-oncology. Survival analysis, for instance, examines whether a molecular feature is associated with how long patients remain alive or free from disease progression. Correlation analysis can test whether two measurements change together, such as an immune-cell score and the expression of an immunoregulatory gene. These statistical relationships are useful starting points, but they do not by themselves prove causation. A gene signature linked to poor survival may be a driver of aggressive disease, a consequence of it, or simply a marker of another underlying process. IOBRportal can organize these analyses and make patterns easier to inspect, but biological validation through experiments, independent cohorts and prospective studies remains necessary before any finding can be translated into patient care.

The researchers describe the system as freely accessible and suitable for both public and user-uploaded data. That combination could be especially useful for laboratories that lack dedicated bioinformatics infrastructure or high-performance computing resources. Cloud execution allows computationally demanding analyses to run remotely and can make a standardized workflow available to users in different institutions. At the same time, cloud-based analysis raises practical questions about data governance, privacy and reproducibility. Clinical datasets may contain sensitive information even when direct identifiers have been removed, and research groups must ensure that data-sharing practices comply with institutional and national rules. Reproducibility also depends on transparent documentation of software versions, reference signatures, preprocessing decisions and statistical settings. The platform’s workflow model may help preserve these details, but users will still need to report them clearly when publishing results.

IOBRportal arrives as cancer biology increasingly moves toward multi-omics, in which measurements from several molecular layers are analyzed together. The appeal is clear: DNA mutations, RNA expression and the cellular composition of a tumor each reveal only part of the disease. Combining them can expose connections that remain invisible when each dataset is studied alone. Yet integration also increases the risk of overinterpreting associations, particularly when large datasets make statistically significant differences easy to detect. The platform should therefore be viewed as an engine for exploration rather than an automated oracle. Its most immediate contribution is practical: it unifies a series of technically demanding steps, provides access to a substantial reference resource and allows investigators to move rapidly from molecular data to candidate explanations. If independent studies confirm the robustness of the patterns it helps uncover, the system could become a widely used gateway for studying how cancer genomes and immune environments interact.

The researchers constructed a high-resolution single-cell atlas from more than 240,000 cells obtained from patients with gastric cancer. Single-cell RNA sequencing enabled them to examine gene-expression programs in individual cells rather than averaging signals across entire tumor samples. This approach revealed extensive cellular diversity within the tumor microenvironment, including multiple macrophage populations, T-cell states and metabolic programs associated with treatment response. Instead of finding that one immune cell type alone predicted outcome, the investigators identified a functional relationship between two macrophage states characterized by high expression of CXCL10 and OLR1.

Macrophages are adaptable immune cells that can respond to signals from cancer cells, stromal tissue and other immune populations. In the gastric tumors examined in the study, Mac-CXCL10 and Mac-OLR1 represented distinct functional states. The relative abundance of these populations was more informative than the simple presence or absence of either one. Tumors with a higher Mac-CXCL10/Mac-OLR1 ratio were more likely to respond to ICB therapy and were associated with longer progression-free survival. This ratio therefore emerged as a potential indicator of the immune conditions that make a tumor more receptive to checkpoint blockade.

The favorable macrophage state was closely linked to a population of interferon-responsive CD8-positive T cells. Interferons are signaling proteins that help coordinate antiviral and antitumor immunity by regulating antigen presentation, immune-cell recruitment and cytotoxic activity. The study suggests that Mac-CXCL10 cells and interferon-responsive CD8-positive T cells form a coordinated “interferon-responsive immune hub” within the tumor microenvironment. In this setting, macrophage-derived signals may help sustain T-cell activation, while activated T cells reinforce an inflammatory circuit capable of supporting tumor-cell recognition and destruction.

The opposing Mac-OLR1 state was associated with lipid-related metabolic programs and features of immune suppression. OLR1, also known as the lectin-like oxidized low-density lipoprotein receptor-1, can bind oxidized lipid particles and is involved in cellular responses to lipid stress. The findings indicate that the accumulation of oxidized lipids in the tumor environment may contribute to the development or maintenance of this macrophage population. Such metabolic pressure could alter macrophage gene expression and behavior, shifting the immune ecosystem away from effective T-cell stimulation.

A central mechanism identified by the researchers involved prostaglandin E₂, or PGE₂, a lipid-derived signaling molecule with broad effects on inflammation and immunity. Mac-OLR1 macrophages were linked to increased PGE₂-related activity. PGE₂ can influence immune-cell migration, cytokine production and T-cell function through signaling pathways that regulate intracellular cyclic AMP and downstream transcriptional responses. In the context of this study, PGE₂ was associated with suppression of interferon signaling in CD8-positive T cells, potentially weakening the production of effector molecules and reducing the ability of these cells to attack malignant cells.

This macrophage–T-cell relationship offers a possible explanation for why some gastric tumors fail to respond even when immune checkpoint molecules are therapeutically blocked. ICB can remove inhibitory signals such as those mediated by PD-1 or related pathways, but this intervention may be insufficient if the surrounding tissue continues to deliver metabolic and inflammatory signals that disable T cells. A PGE₂-rich environment could therefore act as an additional layer of immune resistance, limiting the restoration of T-cell activity after checkpoint inhibition.

The study also raises the possibility of combining immunotherapy with interventions aimed at the tumor’s lipid metabolism or PGE₂ signaling. Strategies that reduce oxidized-lipid stress, alter OLR1-associated macrophage programs or inhibit PGE₂ production and activity could, in principle, shift the macrophage balance toward a more immune-supportive state. Such approaches might enhance the effect of checkpoint blockade, although the study does not establish a treatment regimen for patients. The safety, timing and selectivity of any macrophage- or PGE₂-targeted therapy will require careful evaluation, since these pathways also participate in normal tissue repair and inflammatory control.

The investigators emphasize that their findings require further clinical validation before the macrophage ratio can be used as a routine biomarker. Nevertheless, the work provides a detailed framework for understanding gastric cancer immunotherapy resistance as an ecosystem-level problem. The outcome of treatment may depend not simply on whether immune cells are present, but on how macrophage states, lipid metabolism and T-cell interferon signaling interact within individual tumors. By identifying the Mac-CXCL10/Mac-OLR1 balance and its connection to PGE₂-mediated suppression, the study points toward a more precise form of immunotherapy in which the immune environment itself becomes a therapeutic target.

Subject of Research:
Macrophage states, tumor microenvironment, CD8⁺ T-cell immunity and immunotherapy response in gastric cancer.

Web References:
https://doi.org/10.1016/j.scib.2026.07.049

References:
Science Bulletin, DOI: 10.1016/j.scib.2026.07.049

Image Credits:
© Science Bulletin; created with BioRender.com.

Keywords:
Gastric cancer, immunotherapy, immune checkpoint blockade, tumor microenvironment, macrophages, CXCL10, OLR1, CD8⁺ T cells, interferon signaling, prostaglandin E₂, oxidized lipids, immunosuppression, single-cell atlas.

Immunotherapy has revolutionized cancer treatment by harnessing the body’s own immune system to target and eradicate malignant cells. However, variable patient responses remain a significant hurdle, often attributed to the diverse and dynamic tumor microenvironment. The current study pivots from conventional paradigms by dissecting the spatial and functional relationships between specific immune cell populations localized within the tumor, rather than examining systemic immune parameters alone. Tumor-resident T cells, a subset of lymphocytes adapted to the tumor niche, demonstrated a previously underappreciated cooperative role with dendritic cells—professional antigen-presenting cells responsible for initiating immune responses.

Employing cutting-edge multiplex imaging techniques combined with single-cell transcriptomics, the researchers meticulously mapped the tumor’s immune landscape at unprecedented resolution. This integrative approach allowed them to visualize an intricate cellular architecture where T cells and dendritic cells congregate, forming what they describe as an “in situ archetype.” These cellular assemblies were not mere physical proximities but dynamic functional units exhibiting synergistic signaling pathways critical for maintaining immune surveillance and amplifying anti-tumor activity during immunotherapy.

Functional assays revealed that these tumor-resident T cells possess a unique activation profile characterized by sustained effector functions and memory-like qualities superior to their circulating counterparts. Meanwhile, the dendritic cells within this archetypal niche displayed enhanced antigen processing and presentation capabilities, effectively priming T cells and facilitating their persistence in the hostile tumor milieu. This bidirectional interaction creates a microenvironment supportive of robust immune activity, which correlates strongly with favorable clinical outcomes following checkpoint blockade therapy.

The study further probed the molecular dialogues underpinning this archetype, identifying key cytokines and costimulatory molecules that orchestrate T cell-dendritic cell crosstalk. Notably, the expression of chemokine receptors and ligands appeared finely tuned to sustain cellular recruitment and retention within the tumor. These findings suggest that the spatial organization and communication networks of immune cells are not static but dynamically regulated through intricate feedback loops adjusted by therapeutic interventions.

Importantly, this research offers a compelling explanation for the heterogeneous patient responses witnessed in melanoma immunotherapy. Tumors harboring a well-defined T cell-dendritic cell archetype exhibited more pronounced and durable responses, whereas those lacking this architectural integrity showed resistance and relapse. This correlation proposes that the presence of such cellular niches could serve as predictive biomarkers, guiding personalized therapeutic strategies and enabling clinicians to anticipate treatment efficacy with greater confidence.

The implications of this work extend beyond melanoma, hinting at a universal principle applicable across various solid tumors where immune evasion remains a formidable barrier. By defining the structural and functional blueprint of productive anti-tumor immunity, these insights provide a template to engineer or restore such archetypes therapeutically. Future approaches could involve modulating dendritic cell function or enhancing T cell residency to reprogram the tumor microenvironment towards immunogenicity.

Moreover, the identification of novel molecular targets within these cellular assemblies offers promising avenues for combination therapies. For instance, agents designed to stabilize the T cell-dendritic cell interaction or amplify relevant signaling cascades might synergize with existing checkpoints inhibitors, improving response rates and reducing the prevalence of immune-related adverse effects. This strategic enhancement of intrinsic immune networks opens a new frontier for cancer immunotherapy development.

The study’s technological advancements also set a benchmark for future investigations, leveraging integrative multi-omics and high-dimensional imaging to unravel the complexity of tumor ecosystems. Such comprehensive profiling enables a holistic understanding that transcends traditional reductionist views, capturing the emergent properties of cellular communities that dictate disease progression and treatment response.

In conclusion, the elucidation of an in situ archetype formed by tumor-resident T cells and dendritic cells reshapes our conceptual framework of effective anti-cancer immunity within melanoma. The intricate cellular choreography uncovered underscores the necessity of considering spatial and functional immune architectures in therapeutic design. This discovery heralds a paradigm shift, emphasizing the microenvironmental context that sustains immune competence and offering tangible targets to amplify cancer immunotherapy success.

As immuno-oncology continues to evolve, these findings highlight the pivotal role of tumor-localized immune cell interactions and inspire innovative strategies to harness and mimic nature’s own immunological blueprints. The path forward promises enhanced personalization and efficacy in cancer treatment, ultimately transforming patient outcomes and long-term survivorship. This seminal work marks a significant leap towards unlocking the full potential of the immune system in the fight against melanoma and potentially other malignancies.

Subject of Research: Tumor-resident T cells and dendritic cell interactions during immunotherapy response in melanoma.

Article Title: Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma.

Article References:
Di Pietro, A., Au, L., Crock, P. et al. Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma. Nat Commun (2026). https://doi.org/10.1038/s41467-026-74076-y

Image Credits: AI Generated